Alkala is a German pharmaceutical-grade alkaline mineral powder supplement containing citrates, carbonates, and bicarbonates of calcium, magnesium, potassium, and sodium, formulated to buffer chronic metabolic acidosis and normalize tissue pH. The product line includes Alkala N (designed for systemic/blood buffering) and Alkala S (formulated for intracellular/tissue acidosis), used sequentially in bone healing protocols and chronic inflammatory conditions to restore the physiological pH range necessary for optimal enzyme function, osteoblast activity, and tissue repair.
Think of your body's pH system like a swimming pool's water chemistry. When the pool becomes too acidic (from debris, sweat, weather), the water turns cloudy, surfaces corrode, and nothing works right—the chlorine can't sanitize, algae grows, and the pool structure itself starts breaking down (tiles crack, grout dissolves). The pool manager first adds alkaline chemicals to the main water (Alkala N phase) to restore the overall pH, but that's not enough—the water deep in the filter system, trapped in corners, and soaked into porous surfaces remains acidic. So you need a second chemical (Alkala S phase) specifically designed to penetrate those "cellular compartments" and neutralize the acid trapped inside the system itself. Only after both phases—main water and deep system—are pH-balanced can you expect the pool to self-maintain: surfaces stop eroding, equipment works properly, and the whole system functions as designed. In your body, chronic acidosis (from diet, stress, inflammation) is like that debris constantly acidifying the pool—until you buffer both blood (N) and cells (S), healing simply cannot occur.
Alkala operates through multiple buffering pathways targeting different physiological compartments:
Phase 1: Systemic Buffering (Alkala N)
- Bicarbonate (HCO₃⁻) + citrate ions enter bloodstream → immediately buffer H⁺ ions in plasma and interstitial fluid → HCO₃⁻ + H⁺ → H₂CO₃ → H₂O + CO₂ (exhaled)
- Citrate chelates free calcium → forms soluble calcium citrate complexes → reduces ionized calcium loss from bone (reverses acidosis-driven osteoclast activation)
- Reduced renal acid load → decreased ammonia production in proximal tubule → less cortisol-stimulated glutamine metabolism
- Potassium citrate → replenishes intracellular K⁺ stores depleted during chronic acid buffering (cells normally export K⁺ and import H⁺ to buffer acidosis, causing cellular potassium depletion)
- Magnesium citrate → ATP-Mg²⁺ complex formation improves mitochondrial function → enhances ATP production despite previous acidosis-impaired enzyme activity
Phase 2: Intracellular Buffering (Alkala S)
- Higher magnesium:calcium ratio specifically targets cellular compartments
- Magnesium citrate enters cells via TRPM7 channels → binds to ATP → stabilizes mitochondrial membrane potential → restores Electron transport chain function (acidic pH uncouples ETC, reducing ATP yield)
- Phosphate buffers (from mineral salts) → accumulate in cytoplasm → directly neutralize lactic acid: HPO₄²⁻ + H⁺ → H₂PO₄⁻
- Normalized cellular pH → restores activity of pH-sensitive enzymes (alkaline phosphatase, carbonic anhydrase, Collagenase, matrix metalloproteinases require pH 7.2-7.4 for optimal catalytic function)
- Improved Na⁺/K⁺-ATPase function → restores cellular electrochemical gradients → enables proper nutrient/waste exchange
graph TD
A["Chronic Acidosis<br/>pH <7.35"] --> B["Phase 1: Alkala N"]
B --> C[Blood/ECF Buffering]
C --> D["HCO₃⁻ + H⁺ → H₂O + CO₂"]
C --> E["Citrate chelates Ca²⁺"]
C --> F[Reduced renal acid load]
E --> G["Decreased bone Ca²⁺ loss"]
F --> H[Lower cortisol demand]
C --> I{Systemic pH normalized<br/>pH 7.35-7.45}
I --> J["Phase 2: Alkala S"]
J --> K[Intracellular Buffering]
K --> L["Mg²⁺-citrate enters cells"]
K --> M[Phosphate buffers cytoplasm]
L --> N[Mitochondrial function restored]
M --> O[Lactate neutralization]
N --> P[pH-sensitive enzymes activate]
O --> P
P --> Q["Tissue healing enabled:<br/>osteoblasts, fibroblasts, collagen synthesis"]
G --> Q
H --> Q
Molecular Effects on Bone Healing
- pH normalization (7.35-7.45) → osteoblast alkaline phosphatase activity increases 300% → collagen mineralization proceeds
- Acidic pH (<7.2) → stimulates RANKL expression on osteoblasts → activates osteoclasts via RANK receptor → bone resorption (this pathway is blocked when pH normalizes)
- Citrate incorporation into bone matrix → citrate-apatite crystal formation improves bone strength (citrate represents ~5% of bone organic matrix)
Critical for Bone Healing Protocols: In Leo Pruimboom's bone healing approach, Alkala represents the essential first intervention phase—before circulation support, before supplementation, before expecting any tissue repair. This reflects a fundamental cPNI principle: milieu precedes function. An acidic tissue environment (common in chronic stress, inflammatory conditions, Western diet) makes healing physiologically impossible regardless of nutrient availability.
Evolutionary Mismatch Context: Human physiology evolved on a diet with PRAL (potential renal acid load) of approximately -88 mEq/day (net alkaline from fruits, vegetables, tubers). Modern Western diets generate PRAL of +48 mEq/day (net acidic from grains, dairy, processed foods, meat without plant balance). This chronic acid load triggers compensatory mechanisms: (1) bone calcium mobilization (trading skeletal integrity for pH homeostasis—the Selfish Brain protecting neural function at musculoskeletal expense), (2) muscle catabolism (glutamine release for renal ammonia production), (3) chronic low-grade inflammation (acidic tissue promotes NF-κB activation and IL-6 production).
Clinical Application Logic: The two-phase Alkala protocol addresses the physiological reality that systemic and cellular pH compartments require sequential treatment:
- Weeks 1-4: Alkala N (2-3 scoops/day on empty stomach, >30 minutes from meals) — target urine pH 7.0-7.5 (morning second void)
- Weeks 5-8: Alkala S (after systemic pH stable) — deeper intracellular buffering, target tissue pH normalization (cannot measure directly; assess via symptom improvement and bone healing markers)
Patient Selection: Essential for:
Timing Critical: Must take on empty stomach to avoid neutralizing Gastric acid (HCl) needed for protein digestion and Iron absorption. This is not optional—taking with meals defeats the therapeutic purpose and can cause digestive dysfunction.
Integration with Other Interventions: Deacidification enables subsequent protocol phases:
Monitoring: Track urine pH (second morning void, target 7.0-7.5 during treatment), symptom improvement (pain reduction, mobility increase), bone density markers if appropriate (osteocalcin, C-telopeptide).
- Contains calcium, magnesium, potassium, sodium as citrates, carbonates, and bicarbonates (pharmaceutical-grade mineral salts)
- Alkala N: higher sodium bicarbonate and potassium citrate ratios for extracellular buffering
- Alkala S: higher magnesium citrate ratio for intracellular penetration and mitochondrial support
- Standard dose: 2-3 heaping scoops (6-9g) daily dissolved in 250ml water on empty stomach
- Must wait minimum 30 minutes before eating (60+ minutes optimal) to preserve gastric acid function
- Treatment duration typically 4-8 weeks; severe cases may require 12 weeks
- Reduces PRAL by approximately -120 to -180 mEq/day (more than compensating for typical Western diet acid load)
- Target urine pH during treatment: 7.0-7.5 (second morning void; first void reflects overnight metabolic acids)
- Contraindication: severe renal failure (inability to excrete bicarbonate load), hypercalcemia
- Citrate form provides triple benefit: pH buffering, enhanced mineral absorption (chelation), direct incorporation into bone matrix
- Osteoblast alkaline phosphatase activity peaks at pH 7.4; drops >60% below pH 7.0
- Chronic acidosis (pH <7.35) increases cortisol demand by 30-40% (glutamine metabolism pathway for renal ammonia production requires cortisol activation)
- pH regulation — primary therapeutic mechanism; buffers chronic metabolic acidosis across systemic and cellular compartments
- Calcium — provides bioavailable calcium citrate while simultaneously reducing pathological calcium mobilization from bone during acidotic states
- Magnesium — magnesium citrate component supports ATP production, mitochondrial function, and cellular pH normalization
- Potassium — replenishes intracellular potassium depleted during chronic acid buffering (K⁺/H⁺ exchange)
- Citrate — citrate carrier enhances mineral bioavailability, provides additional buffering capacity, and integrates into bone matrix
- PRAL List — Alkala directly counteracts high dietary PRAL, restoring evolutionary-appropriate net alkaline intake
- Chronic latent acidosis — the primary pathological state Alkala addresses; silent epidemic in modern populations
- Osteoblasts — pH normalization is absolute prerequisite for osteoblast function; alkaline phosphatase requires pH >7.2
- Osteoclasts — acidic tissue (pH <7.2) stimulates osteoclast differentiation via RANKL pathway; buffering reduces bone resorption
- Bone metabolism — bone serves as final pH buffer when diet/kidneys fail; Alkala prevents skeletal sacrifice for acid-base homeostasis
- Lactic acid — phosphate buffers in Alkala S specifically neutralize lactate accumulation in chronically hypoxic or inflamed tissues
- Mitochondria — intracellular pH normalization (Alkala S phase) restores electron transport chain coupling and ATP synthesis efficiency
- ATP production — acidic cytoplasm uncouples mitochondrial ATP synthesis; pH normalization improves energy yield per glucose molecule
- Collagen synthesis — prolyl hydroxylase and lysyl hydroxylase (essential for collagen cross-linking) are pH-sensitive; require pH 7.2-7.4
- Wound healing — all healing phases (hemostasis, inflammation, proliferation, remodeling) require proper tissue pH for enzyme function
- Inflammation — acidic tissue promotes NF-κB activation and pro-inflammatory cytokine production; alkalinization favors resolution
- Cortisol — chronic acidosis increases cortisol demand (glutamine metabolism for renal ammonia production); buffering reduces HPA axis load
- Stress fractures — deacidification protocol mandatory for healing; acidic bone matrix cannot mineralize regardless of calcium/vitamin D status
- Osteoporosis — chronic acid load major contributor; bone calcium mobilized to buffer dietary acid represents slow skeletal dissolution
- Chronic Kidney Disease — reducing renal acid load via alkalinization slows CKD progression; preserves nephron function
- Muscle tissue — chronic acidosis promotes muscle protein catabolism (glutamine release for renal buffering); normalization preserves lean mass
- Exercise — high-intensity training generates lactate; chronic athletes benefit from alkalinization to prevent tissue acidification
- Insulin resistance — acidic tissue impairs insulin signaling; pH normalization improves glucose disposal
- Internal Milieu — Alkala protocol exemplifies Claude Bernard's principle: stable internal environment (pH) enables cellular function
- Selfish Brain — brain pH protection (via bone calcium mobilization during chronic acidosis) sacrifices musculoskeletal health; Alkala breaks this trade-off
- Evolutionary mismatch — modern diet acid load (PRAL +48 mEq/day) versus ancestral alkaline load (PRAL -88 mEq/day) creates chronic disease substrate
- Intervention Options for Acidosis — Alkala represents pharmacological-grade intervention; part of comprehensive deacidification strategy
- Alkaline phosphatase — osteoblast marker enzyme; activity indicates bone formation capacity; pH-dependent (optimal 7.4)
- Regulator — often paired with Alkala in protocols; addresses different aspects of tissue healing (immune modulation versus pH buffering)